Clinical Trials Directory

Trials / Completed

CompletedNCT00099567

Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline

Status
Completed
Phase
Study type
Observational
Enrollment
2,632 (planned)
Sponsor
National Institute on Aging (NIA) · NIH
Sex
All
Age
70 Years – 79 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine if the metabolic syndrome is a risk factor for cognitive decline and if this association is modified by inflammation.

Detailed description

The metabolic syndrome is a clustering of several commonly occurring disorders that include abdominal obesity, high triglycerides, low HDL cholesterol, high blood pressure, and insulin resistance. This study was conducted to determine if, as hypothesized, the presence of the metabolic syndrome is associated with more cognitive decline and greater risk of developing cognitive impairment, and whether this risk is affected by the level of inflammatory markers in the blood. This 5-year prospective observational study was conducted from 1997 to 2002 at community clinics in two locations. A total of 2632 black and white participants, aged 70 to 79 years, were recruited from the 3075 participants in the Health, Aging and Body Composition (ABC) study conducted during the same period. Participants were screened for presence of metabolic syndrome, cognitive status, inflammatory markers, and a clinic examination was administered, when the study began and at the year 3 and 5 follow-up visits.

Conditions

Timeline

Start date
1997-01-01
Completion
2002-12-01
First posted
2004-12-17
Last updated
2005-11-01

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00099567. Inclusion in this directory is not an endorsement.

Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline (NCT00099567) · Clinical Trials Directory